VRTX Vertex Pharmaceuticals
Nasdaq · SEC CIK 875320 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $158.38M 53 sales by 13 insiders
- Filings on record
- 531 since 2021-07-16, latest 2026-09-10 16:31
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| LEIDEN JEFFREY M | Executive COB, Dir | — | $60.94M |
| Sachdev Amit | EVP Chief Patient, Ext Af Off | — | $28.38M |
| Kewalramani Reshma | CEO, Pres, Dir | — | $19.74M |
| Bozic Carmen | EVP, CMO | — | $11.31M |
| WAGNER CHARLES F JR | EVP, CO, FO | — | $10.78M |
| Tatsis Ourania | EVP, Chief Reg, Quality Off | — | $6.51M |
| McKechnie Duncan | EVP, Chief Commercial Off | — | $5.66M |
| Biller Jonathan | EVP, CLO | — | $4.08M |
| Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | — | $3.60M |
| Bunnage Mark E. | EVP, CSO | — | $3.00M |
Transactions 621
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-14 | 2025-02-12 | VRTX | Bozic Carmen | EVP, CMO | A - Grant | $0.00 | +5,546 | 42.9K | +15% | $0 | |
| 2025-02-14 | 2025-02-12 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | A - Grant | $0.00 | +7,209 | 32.6K | +28% | $0 | |
| 2025-02-14 | 2025-02-13 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | F - Tax | $450.83 | -2,525 | 30.1K | -8% | -$1.14M | |
| 2025-02-14 | 2025-02-12 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | A - Grant | $0.00 | +6,211 | 76.8K | +9% | $0 | |
| 2025-02-14 | 2025-02-12 | VRTX | WAGNER CHARLES F JR | EVP, CFO | A - Grant | $0.00 | +6,655 | 65.5K | +11% | $0 | |
| 2025-02-14 | 2025-02-12 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | A - Grant | $0.00 | +6,211 | 70.2K | +10% | $0 | |
| 2025-02-14 | 2025-02-12 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | A - Grant | $0.00 | +6,211 | 29.4K | +27% | $0 | |
| 2025-02-14 | 2025-02-12 | VRTX | ALTSHULER DAVID | EVP, CSO | A - Grant | $0.00 | +5,324 | 48.4K | +12% | $0 | |
| 2025-02-14 | 2025-02-12 | VRTX | Arbuckle Stuart A | EVP, COO | A - Grant | $0.00 | +7,903 | 77.4K | +11% | $0 | |
| 2025-02-14 | 2025-02-12 | VRTX | Biller Jonathan | EVP, CLO | A - Grant | $0.00 | +4,437 | 20.8K | +27% | $0 | |
| 2025-02-14 | 2025-02-12 | VRTX | Ambrose Kristen | SVP, CAO | A - Grant | $0.00 | +2,080 | 12.0K | +21% | $0 | |
| 2025-02-12 | 2025-02-10 | VRTX | ALTSHULER DAVID | EVP, CSO | F - Tax | $467.98 | -2,142 | 43.1K | -5% | -$1.00M | |
| 2025-02-12 | 2025-02-10 | VRTX | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $467.98 | -2,649 | 58.9K | -4% | -$1.24M | |
| 2025-02-12 | 2025-02-10 | VRTX | Ambrose Kristen | SVP, CAO | F - Tax | $467.98 | -591 | 11.3K | -5% | -$276.6K | |
| 2025-02-12 | 2025-02-11 | VRTX | Ambrose Kristen | SVP, CAO | S - Sale | $459.83 | -1,376 | 9,953 | -12% | -$632.7K | |
| 2025-02-12 | 2025-02-10 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | F - Tax | $467.98 | -2,056 | 70.6K | -3% | -$962.2K | |
| 2025-02-12 | 2025-02-10 | VRTX | Bozic Carmen | EVP, CMO | F - Tax | $467.98 | -2,142 | 37.3K | -5% | -$1.00M | |
| 2025-02-12 | 2025-02-10 | VRTX | Biller Jonathan | EVP, CLO | F - Tax | $467.98 | -1,632 | 19.8K | -8% | -$763.7K | |
| 2025-02-12 | 2025-02-11 | VRTX | Biller Jonathan | EVP, CLO | S - Sale | $459.87 | -3,433 | 16.3K | -17% | -$1.58M | |
| 2025-02-12 | 2025-02-10 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $467.98 | -8,300 | 116.9K | -7% | -$3.88M | |
| 2025-02-12 | 2025-02-10 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | F - Tax | $467.98 | -876 | 25.0K | -3% | -$410.0K | |
| 2025-02-12 | 2025-02-11 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | S - Sale | $459.83 | -1,747 | 23.2K | -7% | -$803.3K | |
| 2025-02-12 | 2025-02-10 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $467.98 | -2,143 | 64.3K | -3% | -$1.00M | |
| 2025-02-12 | 2025-02-11 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $459.83 | -310 | 64.0K | -0.5% | -$142.5K | |
| 2025-02-12 | 2025-02-10 | VRTX | Arbuckle Stuart A | EVP, COO | F - Tax | $467.98 | -3,220 | 69.5K | -4% | -$1.51M | |
| M | 2025-02-06 | 2025-02-04 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | A - Grant | $0.00 | +15.3K | 65.5K | +31% | $0 |
| M | 2025-02-06 | 2025-02-04 | VRTX | Bozic Carmen | EVP, CMO | A - Grant | $0.00 | +16.2K | 39.4K | +70% | $0 |
| M | 2025-02-06 | 2025-02-04 | VRTX | WAGNER CHARLES F JR | EVP, CFO | A - Grant | $0.00 | +17.4K | 61.5K | +39% | $0 |
| 2025-02-06 | 2025-02-04 | VRTX | Biller Jonathan | EVP, CLO | A - Grant | $0.00 | +4,744 | 21.4K | +28% | $0 | |
| 2025-02-06 | 2025-02-04 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | A - Grant | $0.00 | +15.4K | 25.4K | +154% | $0 | |
| M | 2025-02-06 | 2025-02-04 | VRTX | ALTSHULER DAVID | EVP, CSO | A - Grant | $0.00 | +19.4K | 45.2K | +75% | $0 |
| M | 2025-02-06 | 2025-02-04 | VRTX | Arbuckle Stuart A | EVP, COO | A - Grant | $0.00 | +23.1K | 64.3K | +56% | $0 |
| M | 2025-02-06 | 2025-02-04 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | A - Grant | $0.00 | +17.4K | 59.4K | +41% | $0 |
| M | 2025-02-06 | 2025-02-04 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | A - Grant | $0.00 | +49.4K | 125.2K | +65% | $0 |
| M | 2025-02-06 | 2025-02-04 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | A - Grant | $0.00 | +9,876 | 25.8K | +62% | $0 |
| M | 2025-02-06 | 2025-02-04 | VRTX | Ambrose Kristen | SVP, CAO | A - Grant | $0.00 | +4,420 | 10.1K | +78% | $0 |
| 2024-11-19 | 2024-11-15 | VRTX | ALTSHULER DAVID | EVP, CSO | S - Sale | $478.56 | -15 | 25.8K | -0.1% | -$7,178 | |
| 2024-11-13 | 2024-11-11 | VRTX | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $518.27 | -3,000 | 44.1K | -6% | -$1.55M | |
| 2024-11-12 | 2024-11-08 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $515.00 | -15.2K | 75.8K | -17% | -$7.83M | |
| 2024-10-03 | 2024-10-02 | VRTX | Biller Jonathan | EVP, CLO | S - Sale | $461.66 | -999 | 16.7K | -6% | -$461.2K | |
| 2024-10-03 | 2024-10-01 | VRTX | Biller Jonathan | EVP, CLO | F - Tax | $466.84 | -630 | 17.6K | -3% | -$294.1K | |
| D | 2024-09-04 | 2024-08-30 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale+OE | $500.00 | -646 | 4,435 | -13% | -$323.0K |
| D | 2024-09-04 | 2024-08-30 | VRTX | Bhatia Sangeeta N. | Dir | M - OptEx | $152.74 | +646 | 5,081 | +15% | +$98.7K |
| 2024-09-04 | 2024-08-30 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | S - Sale | $499.00 | -3,784 | 9,994 | -27% | -$1.89M | |
| D | 2024-08-12 | 2024-08-08 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale+OE | $466.29 | -1,292 | 4,435 | -23% | -$602.4K |
| D | 2024-08-12 | 2024-08-08 | VRTX | Bhatia Sangeeta N. | Dir | M - OptEx | $152.74 | +1,292 | 5,727 | +29% | +$197.3K |
| 2024-08-08 | 2024-08-07 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $476.75 | -2,280 | 23.3K | -9% | -$1.09M | |
| D | 2024-08-02 | 2024-08-01 | VRTX | SACHS BRUCE I | Dir | M - OptEx | $125.71 | +5,295 | 45.3K | +13% | +$665.6K |
| D | 2024-08-02 | 2024-08-01 | VRTX | SACHS BRUCE I | Dir | S - Sale+OE | $508.00 | -5,295 | 40.0K | -12% | -$2.69M |
| 2024-08-01 | 2024-07-30 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $505.00 | -15.2K | 91.0K | -14% | -$7.68M | |
| 2024-07-25 | 2024-07-24 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $488.46 | -2,280 | 25.5K | -8% | -$1.11M | |
| 2024-07-24 | 2024-07-22 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $497.00 | -15.2K | 106.2K | -13% | -$7.56M | |
| 2024-07-12 | 2024-07-10 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $487.34 | -2,280 | 27.8K | -8% | -$1.11M | |
| 2024-06-28 | 2024-06-26 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $471.72 | -2,280 | 30.1K | -7% | -$1.08M | |
| 2024-06-13 | 2024-06-11 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | F - Tax | $481.96 | -6,824 | 23.3K | -23% | -$3.29M | |
| 2024-06-13 | 2024-06-12 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | S - Sale | $478.00 | -7,288 | 16.0K | -31% | -$3.48M | |
| 2024-06-13 | 2024-06-12 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $478.00 | -2,280 | 32.4K | -7% | -$1.09M | |
| I | 2024-06-07 | 2024-06-05 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | G - Gift | $0.00 | -4,600 | 0 | -100% | $0 |
| 2024-06-05 | 2024-06-03 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $460.00 | -2,175 | 49.1K | -4% | -$1.00M | |
| 2024-06-05 | 2024-06-03 | VRTX | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $460.00 | -3,250 | 47.1K | -6% | -$1.50M | |
| M | 2024-06-03 | 2024-05-30+ | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $441.99 | -4,600 | 51.3K | -8% | -$2.03M |
| 2024-05-31 | 2024-05-29 | VRTX | Bozic Carmen | EVP, CMO | S - Sale | $445.56 | -2,280 | 34.7K | -6% | -$1.02M | |
| 2024-05-30 | 2024-05-28 | VRTX | WAGNER CHARLES F JR | EVP, CFO | S - Sale | $454.79 | -3,250 | 50.4K | -6% | -$1.48M | |
| D | 2024-05-29 | 2024-05-24 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale+OE | $457.00 | -1,565 | 121.4K | -1% | -$715.2K |
| D | 2024-05-29 | 2024-05-24 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | M - OptEx | $187.53 | +1,565 | 122.9K | +1% | +$293.5K |
| D | 2024-05-24 | 2024-05-22 | VRTX | SACHS BRUCE I | Dir | M - OptEx | $93.51 | +7,073 | 47.1K | +18% | +$661.4K |
| D | 2024-05-24 | 2024-05-22 | VRTX | SACHS BRUCE I | Dir | S - Sale+OE | $448.00 | -7,073 | 40.0K | -15% | -$3.17M |
| 2024-05-22 | 2024-05-20 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale | $447.00 | -15.2K | 121.4K | -11% | -$6.80M | |
| 2024-05-17 | 2024-05-15 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | S - Sale | $430.93 | -32 | 55.3K | -0.1% | -$13.8K | |
| 2024-05-17 | 2024-05-15 | VRTX | ALTSHULER DAVID | EVP, CSO | S - Sale | $430.93 | -54 | 25.8K | -0.2% | -$23.3K | |
| 2024-05-17 | 2024-05-15 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $430.93 | -69 | 49.7K | -0.1% | -$29.7K | |
| 2024-05-17 | 2024-05-15 | VRTX | Schneider Jennifer | Dir | A - Grant | $0.00 | +922 | 922 | New | $0 | |
| 2024-05-16 | 2024-05-14 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | A - Grant | $0.00 | +14.1K | 30.1K | +88% | $0 | |
| D | 2024-05-03 | 2024-05-01 | VRTX | MCKENZIE DIANA | Dir | A - Grant | $0.00 | +1,001 | 3,604 | +38% | $0 |
| D | 2024-05-03 | 2024-05-01 | VRTX | MCKENZIE DIANA | Dir | D - Sale to Iss | — | -1,168 | 2,436 | -32% | — |
| D | 2024-05-03 | 2024-05-01 | VRTX | Thornberry Nancy | Dir | A - Grant | $0.00 | +501 | 1,637 | +44% | $0 |
| 2024-05-03 | 2024-05-02 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $402.95 | -467 | 4,435 | -10% | -$188.2K | |
| 2024-05-03 | 2024-05-01 | VRTX | Bhatia Sangeeta N. | Dir | A - Grant | $0.00 | +1,001 | 4,902 | +26% | $0 | |
| 2024-05-03 | 2024-05-01 | VRTX | CARNEY LLOYD | Dir | A - Grant | $0.00 | +1,001 | 6,319 | +19% | $0 | |
| D | 2024-05-03 | 2024-05-01 | VRTX | Upadhyay Suketu | Dir | D - Sale to Iss | — | -1,168 | 2,559 | -31% | — |
| D | 2024-05-03 | 2024-05-01 | VRTX | Upadhyay Suketu | Dir | A - Grant | $0.00 | +1,001 | 3,727 | +37% | $0 |
| 2024-04-03 | 2024-04-01 | VRTX | Ambrose Kristen | SVP, CAO | F - Tax | $418.10 | -225 | 7,740 | -3% | -$94.1K | |
| 2024-04-03 | 2024-04-02 | VRTX | Ambrose Kristen | SVP, CAO | S - Sale | $419.00 | -240 | 7,500 | -3% | -$100.6K | |
| 2024-02-27 | 2024-02-23 | VRTX | Bozic Carmen | EVP, CMO | F - Tax | $431.79 | -3,309 | 36.9K | -8% | -$1.43M | |
| 2024-02-27 | 2024-02-23 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | F - Tax | $431.79 | -2,469 | 58.3K | -4% | -$1.07M | |
| 2024-02-27 | 2024-02-26 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | S - Sale | $425.70 | -3,004 | 55.3K | -5% | -$1.28M | |
| 2024-02-27 | 2024-02-26 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $425.70 | -5,034 | 49.7K | -9% | -$2.14M | |
| 2024-02-27 | 2024-02-23 | VRTX | Arbuckle Stuart A | EVP, COO | F - Tax | $431.79 | -4,714 | 54.7K | -8% | -$2.04M | |
| 2024-02-27 | 2024-02-26 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $425.70 | -4,239 | 25.8K | -14% | -$1.80M | |
| 2024-02-27 | 2024-02-23 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $431.79 | -3,970 | 30.1K | -12% | -$1.71M | |
| 2024-02-27 | 2024-02-23 | VRTX | Ambrose Kristen | SVP, CAO | F - Tax | $431.79 | -828 | 8,848 | -9% | -$357.5K | |
| 2024-02-27 | 2024-02-26 | VRTX | Ambrose Kristen | SVP, CAO | S - Sale | $425.70 | -883 | 7,965 | -10% | -$375.9K | |
| 2024-02-27 | 2024-02-23 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $431.79 | -3,309 | 56.2K | -6% | -$1.43M | |
| 2024-02-27 | 2024-02-26 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $425.70 | -354 | 55.8K | -0.6% | -$150.7K | |
| 2024-02-27 | 2024-02-23 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | F - Tax | $431.79 | -1,654 | 16.9K | -9% | -$714.2K | |
| 2024-02-27 | 2024-02-26 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | S - Sale | $425.70 | -883 | 16.0K | -5% | -$375.9K | |
| 2024-02-27 | 2024-02-23 | VRTX | WAGNER CHARLES F JR | EVP, CFO | F - Tax | $431.79 | -3,309 | 53.6K | -6% | -$1.43M | |
| 2024-02-27 | 2024-02-23 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $431.79 | -9,386 | 136.5K | -6% | -$4.05M | |
| 2024-02-23 | 2024-02-21 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | S - Sale | $421.77 | -3,191 | 60.8K | -5% | -$1.35M | |
| 2024-02-23 | 2024-02-21 | VRTX | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $421.77 | -3,002 | 34.0K | -8% | -$1.27M |
Purchase Sale Sale after option exercise All abbreviations